title: A fluorescence-based high-throughput screening assay for identifying human cytomegalovirus inhibitors.
abstract: Human cytomegalovirus (HCMV) is a common opportunistic pathogen that can cause devastating -morbidity and mortality amongst neonates and immune-compromised patients. The current standard of care for HCMV infection is limited to four antiviral compounds that have major limitations in terms of long--term use, toxicity, and use during pregnancy. To provide patients with alternative treatment options to decrease HCMV-related morbidity and mortality, new drugs with novel modes of action are warranted. Here, we describe a validated high-throughput fluorescence antiviral screening assay based on infection of fibroblast cells with a fluorescently tagged reference strain of HCMV (AD169-GFP) to screen and profile HCMV inhibitors.
authors.affiliation: Janssen Infectious Diseases-Diagnostics BVBA, Johnson & Johnson Corporation, Beerse, Belgium.
authors.forename: Christel
authors.initials: C
authors.lastname: Van den Eynde
authors.forename: Ellen
authors.initials: E
authors.lastname: Van Damme
authors.forename: Tania
authors.initials: T
authors.lastname: Ivens
authors.forename: Edwin Yunhao
authors.initials: EY
authors.lastname: Gong
mesh_terms: D000998:Antiviral Agents / Q000494:pharmacology* / Q000633:toxicity; D002460:Cell Line; D003587:Cytomegalovirus / Q000187:drug effects*; D057166:High-Throughput Screening Assays; D006801:Humans; D008826:Microbial Sensitivity Tests / Q000379:methods*; D008856:Microscopy, Fluorescence; D013050:Spectrometry, Fluorescence
chemical_list: D000998:Antiviral Agents